CompoAtlas

AMYGDALUS REPETA

Food supplement declared in France, declaration No 2018-12-370, decision dated 10 December 2018

AMYGDALUS REPETA is a food supplement declared in France. Status: déclaré en France, commercialisation possible : l'administration ne s'est pas opposée à la déclaration (ce n'est ni une autorisation ni une évaluation de sécurité). 1 rule of use applies to its ingredients (limits and warnings).

Brand
not provided
Food business operator placing the product on the market
SABAHPHARM
Status
Déclaré en France, commercialisation possible : l'administration ne s'est pas opposée à la déclaration (ce n'est ni une autorisation ni une évaluation de sécurité)
Form
Gélule
Daily dose
4 gélules par jour
Directions for use
3 à 4 gélules par jour avec un verre d'eau, 20 minutes avant les repas.
Not recommended for (according to the manufacturer)
Adolescents (moins de 18 ans), Femmes allaitantes, Allergie aux dérivés salicylés, Enfants (moins de 12 ans), Enfants en bas âge (1 à 3 ans), Femmes enceintes, Nourrissons (moins de 1 an), Sous anticoagulants
Objectives stated by the manufacturer (these are not authorised claims)
Voies respiratoires, Immunité

Declaration 292438, procedure Article 15. Compl'Alim, food supplement declarations (France), retrieved 23 October 2026.

Regulatory points

Declared composition

Plants

PlantPartPreparationPer day
Agrimonia eupatoria L.Parties aériennesExtrait sec hydroalcoolique400 mg
Salix alba L.EcorceExtrait sec hydroalcoolique400 mg
Ribes nigrum L.FeuilleExtrait sec hydroalcoolique320 mg
Juglans regia L.PéricarpeExtrait sec hydroalcoolique320 mg
Echinacea purpurea (L.) MoenchParties aériennesExtrait sec hydroalcoolique280 mg
Arctium lappa L.RacineExtrait sec hydroalcoolique280 mg

Vitamins and minerals

Compl'Alim does not publish vitamin and mineral doses. The references below help you read the product label: EFSAEuropean Food Safety Authority. safety limit for adults and maximum dose set in France per product (Order of 9 May 2006, not revised since November 2006).

Declared formNutrientEFSA limit, adults Maximum dose in France
Sulfate de cuivreCuivre5,000 µg2,000 µg
NicotinamideNicotinamide (vitamine B3)900 mg54 mg

Additives

E460, E470b

Other ingredients

gélatine

List from the declaration, administrative decision dated (Compl'Alim, food supplement declarations (France)).

Photograph the packaging

Label warnings

Déconseillé aux enfants, adolescents, femmes enceintes ou allaitantes ainsi qu’aux personnes souffrant d’allergie aux dérivés salicylés ou sous traitement anticoagulant.

This information reproduces the manufacturer's declaration to the administration (DGAL). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.

Official warnings (Health Canada)

Health Canada publishes warnings on these ingredients:

  • Salix alba L.
    Read the warning, when it applies and the studies cited

    WILLOW BARK

    Route of administration: Oral

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have asthma or peptic ulcer disease (EMA 2017).

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood thinners or products containing salicylates (e.g., acetylsalicylic acid or non-steroidal anti-inflammatory drugs) (EMA 2017).

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    Contraindications

    Do not use if you are pregnant or breastfeeding (EMA 2017; Brinker 2010; Wichtl 2004; ESCOP 2003; Barnes et al. 2002; Blumenthal et al. 2000).

    6 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Do not use if you are allergic to salicylates (EMA 2017; Brinker 2010; Wichtl 2004, ESCOP 2003; Barnes et al. 2002; Blumenthal et al. 2000).

    6 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Known adverse reactions

    When using this product you may experience gastrointestinal discomfort/disturbances (EMA 2017; Brinker 2010; Wichtl 2004; ESCOP 2003; Barnes et al. 2002; Blumenthal et al. 2000)

    6 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Health Canada monograph dated 28 March 2024

  • Echinacea purpurea (L.) Moench
    Read the warning, when it applies and the studies cited

    ECHINACEA - ECHINACEA PURPUREA

    Route of administration: Oral

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have a progressive systemic disease such as tuberculosis, collagenosis, multiple sclerosis, or an immune system disorder (EMA 2015; Gardner and McGuffin 2013; Brinker 2010).

    3 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking medications to suppress the immune system (Brinker 2010; Mills and Bone 2005).

    2 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Known adverse reactions

    Condition of application: Preparations containing herb top.

    Stop use if hypersensitivity/allergy occurs (MHRA 2018; EMA 2015; Kligler 2003; WHO 1999).

    4 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Health Canada monograph dated 19 December 2025

  • Arctium lappa L.
    Read the warning, when it applies and the studies cited

    Burdock - Arctium Lappa - Oral

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are breastfeeding.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have diabetes (Brinker 2010; Barnes et al. 2007).

    2 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Contraindications

    Do not use if you are pregnant (Brinker 2010).

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    Known adverse reactions

    Condition of application: All products.

    Stop use if hypersensitivity/allergy occurs (Brinker 2010).

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    Condition of application: All products except those making a diuretic claim.

    When using this product diuretic effect may occur.

    Health Canada monograph dated 19 December 2025

    BURDOCK - ARCTIUM LAPPA - Topical

    Cautions and warnings

    For external use only.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (Brinker 2010; Barnes 2007).

    2 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    When using this product avoid contact with eyes and mucous membranes. If contact occurs, rinse thoroughly with water.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Keep out of reach of children. If swallowed, call a poison control centre or get medical help right away.

    Known adverse reactions

    Stop use if hypersensitivity/allergy occurs (Brinker 2010).

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    Health Canada monograph dated 28 February 2025

They concern the ingredient, not this product or its dose. They do not replace medical advice.

Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.

List recorded in 2018. Photograph the packaging to check whether it has changed.

Enter to analyse, Shift+Enter for a new line